Noteworthy, CRISPR-Cas9 targeting of caspase-2 in human ovarian carcinomas cells enhanced phosphorylation of RIPK1 and MLKL, indicating caspase-2 as a negative regulator of necroptotic cell death to be an important candidate in therapeutic applications (Zamaraev et al. 2018). Here, CASP2 is linked to ovarian carcinoma.